Home / Market News / $DGX

$DGX news and market catalysts

The 14 most recent market catalysts affecting $DGX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

14 catalysts 5 high impact 10 bullish 1 bearish Healthcare
Nov 6, 2026 Corporate Catalyst Bullish Impact 55
Quest Diagnostics Settles Illegal Kickback Allegations for $13 Million
Quest Diagnostics (DGX) has agreed to pay $13 million to settle allegations of providing illegal kickbacks to healthcare executives for business referrals, specifically involving f…
Oct 28, 2026 Corporate Catalyst Bullish Impact 55
Evercore ISI Adjusts Price Target on Quest Diagnostics to $240 From $235
Evercore ISI adjusted its price target for Quest Diagnostics (DGX) upwards from $235 to $240. This change signifies a slightly more optimistic outlook from the analyst firm, likely…
Oct 27, 2026 Corporate Catalyst Bullish Impact 55
Rothschild & Co Redburn Adjusts Price Target on Quest Diagnostics to $279 From $251
Rothschild & Co Redburn has raised its price target for Quest Diagnostics (DGX) from $251 to $279. This adjustment signals a more favorable view from the analyst firm on the compan…
Oct 23, 2026 Corporate Catalyst Bearish Impact 65
Quest Diagnostics Reports Cyber Breach Affecting Quanum Lab Services Manager
Quest Diagnostics has reported a cyber breach affecting its Quanum Lab Services Manager system, which is used for ordering tests and retrieving results. This is significant because…
Oct 22, 2026 Corporate Catalyst Bullish Impact 85
Quest Diagnostics Reports Q3 2026 Financial Results and Raises Full-Year Guidance
Quest Diagnostics reported Q3 2026 adjusted EPS of $3.00, exceeding the FactSet consensus of $2.87, and revenue of $3.10 billion, above the $3.05 billion expectation. This strong p…
Oct 7, 2026 Corporate Catalyst Bullish Impact 55
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260
Barclays analyst Luke Sergott maintained an 'Overweight' rating on Quest Diagnostics (DGX) and raised the price target from $250 to $260. This action signals continued confidence i…
Sep 22, 2026 Corporate Catalyst Neutral Impact 75
CMS Targets $1 Billion in Annual Savings With new Medicare Lab Payment Rates — Here’s What Could Change in 2027
CMS is proposing to reduce Medicare payments for laboratory services by an estimated $1 billion annually, bringing them closer to private-sector rates. This is a significant develo…
Sep 21, 2026 Corporate Catalyst Neutral Impact 55
Quest Diagnostics Study Indicates That Nearly One In Three Patients With Antibodies Against Bacterium That Causes Lyme Disease Also Had Antibodies Against One Or More Additional Tick-Borne Pathogens
Quest Diagnostics (DGX) released a study indicating that nearly 30% of patients with Lyme disease antibodies also have antibodies for other tick-borne pathogens. This finding is si…
Jul 24, 2026 Corporate Catalyst Bullish Impact 55
Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260
Mizuho analyst Ann Hynes maintained an 'Outperform' rating on Quest Diagnostics (DGX) and raised the price target from $235 to $260. This analyst action signals continued confidenc…
Jul 24, 2026 Corporate Catalyst Bullish Impact 55
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $250
Barclays analyst Luke Sergott maintained an 'Overweight' rating on Quest Diagnostics (DGX) and raised the price target from $230 to $250. This action signals continued confidence f…
Jul 23, 2026 Corporate Catalyst Bullish Impact 92
Americans Are Buying More Preventive Health Tests—and Quest Diagnostics Is Winning
Quest Diagnostics (DGX) delivered a significant beat on its Q2 earnings and revenue, surpassing analyst consensus. This strong performance was fueled by a 13.1% increase in total r…
Jul 23, 2026 Corporate Catalyst Neutral Impact 85
Transcript: Quest Diagnostics Q2 2026 Earnings Conference Call
Quest Diagnostics' Q2 2026 earnings call transcript reveals a significant 10.2% revenue increase and a subsequent upward revision of its full-year guidance. This positive developme…
Jul 23, 2026 Corporate Catalyst Bullish Impact 92
Quest Diagnostics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance above estimates.
This headline is a significant corporate catalyst for Quest Diagnostics (DGX), indicating strong fundamental performance and an optimistic future outlook. The better-than-expected …
Jul 23, 2026 Corporate Catalyst Bullish Impact 92
Quest Diagnostics Q2 Adj. EPS $3.12 Beats $2.83 Estimate, Sales $3.043B Beat $2.973B Estimate
Quest Diagnostics (DGX) announced Q2 adjusted EPS of $3.12, surpassing the $2.83 consensus estimate by over 10%. Additionally, quarterly sales reached $3.043 billion, exceeding the…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.